The Hen's Egg Test on Chorioallantoic Membrane: An Alternative Assay for the Assessment of the Irritating Effect of Vaccine Adjuvants

被引:62
作者
Batista-Duharte, Alexander [1 ,2 ]
Jorge Murillo, Gisela [1 ]
Marques Perez, Ulpiano [1 ]
Naranjo Tur, Enieyis [1 ]
Portuondo, Deivys Fuentes [2 ]
Tellez Martinez, Bruno [3 ]
Tellez-Martinez, Damiana [4 ]
Betancourt, Juan E. [1 ]
Perez, Oliver [5 ]
机构
[1] Med Sci Univ Santiago de Cuba, Toxicol & Biomed Ctr TOXIMED, Santiago De Cuba, Cuba
[2] Sao Paulo Estate Univ UNESP, Fac Pharmaceut Sci, Araraquara, Brazil
[3] Univ Oriente, Dept Biol, Fac Nat Sci, Santiago De Cuba, Cuba
[4] Univ Oriente, Fac Chem Enginery, Santiago De Cuba, Cuba
[5] Univ Med Sci, Dept Immunol, Havana, Cuba
关键词
HET-CAM; irritation; adjuvants; local reactions; MUCOSAL VACCINATION; IMMUNE-RESPONSES; IN-VITRO; TOXICITY; MODEL; SAPONINS; TISSUE; CAM;
D O I
10.1177/1091581816672187
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Local reactions are the most frequent adverse event associated with vaccines. Adjuvants are major constituents of many vaccines and they are frequently involved in these reactions, associated with their irritating effect and the stimulation of local inflammation. The hen's egg test on chorioallantoic membrane (HET-CAM) is an alternative toxicological method widely used to determine ocular irritation potential, but very few studies have demonstrated the utility of this method for assessing the irritant properties of vaccine adjuvants. In this work, known/experimental adjuvants were evaluated by both HET-CAM and an in vivo local toxicity study in mice to compare irritation scores to determine whether there was a correlation (Pearson test). Based on these data (r = 0.9034; P < 0.0001), the HET-CAM assay can be used as an alternate method for the prediction of the local toxicity potential of adjuvant candidates to be used in vaccines.
引用
收藏
页码:627 / 633
页数:7
相关论文
共 46 条
  • [1] [Anonymous], 2013, Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines
  • [2] Dose site reactions and related findings after vaccine administration in safety studies
    Baldrick, Paul
    [J]. JOURNAL OF APPLIED TOXICOLOGY, 2016, 36 (08) : 980 - 990
  • [3] Adjuvant effect of Cliptox™ on the protective immune response induced by an inactivated vaccine against foot and mouth disease virus in mice
    Batista, A.
    Quattrocchi, V.
    Olivera, V.
    Langellotti, C.
    Pappalardo, J. S.
    Di Giacomo, S.
    Mongini, C.
    Portuondo, D.
    Zamorano, P.
    [J]. VACCINE, 2010, 28 (38) : 6361 - 6366
  • [4] Immunological adjuvants. Determinant factors in the efficacy-toxicity ratio of the contemporary vaccines
    Batista-Duharte, Alexander
    Lastre, Miriam
    Perez, Oliver
    [J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2014, 32 (02): : 106 - 114
  • [5] An approach to local immunotoxicity induced by adjuvanted vaccines
    Batista-Duharte, Alexander
    Portuondo, Deivys
    Carlos, Iracilda Zeppone
    Perez, Oliver
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2013, 17 (03) : 526 - 536
  • [6] Progress in understanding adjuvant immunotoxicity mechanisms
    Batista-Duharte, Alexander
    Lindblad, Erik B.
    Oviedo-Orta, Ernesto
    [J]. TOXICOLOGY LETTERS, 2011, 203 (02) : 97 - 105
  • [7] The modified HET-CAM as a model for the assessment of the inflammatory response to tissue tolerable plasma
    Bender, Claudia
    Partecke, Lars-Ivo
    Kindel, Eckhard
    Doering, Friederike
    Lademann, Juergen
    Heidecke, Claus-Dieter
    Kramer, Axel
    Huebner, Nils-Olaf
    [J]. TOXICOLOGY IN VITRO, 2011, 25 (02) : 530 - 537
  • [8] Chorioallantoic membrane angiogenesis model for tissue engineering: A new twist on a classic model
    Borges, J
    Tegtmeier, FT
    Padron, NT
    Mueller, MC
    Lang, EM
    Stark, GB
    [J]. TISSUE ENGINEERING, 2003, 9 (03): : 441 - 450
  • [9] Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies
    Brennan, FR
    Dougan, G
    [J]. VACCINE, 2005, 23 (24) : 3210 - 3222
  • [10] Committee for Medicinal Products for Human Use (CHMP), 2005, EMEACHMPVEG134716200